1st Quarter - Report

TARPLIN STRATEGIES LLC for GENENTECH, INC.

Firm
Client
Income
$75,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Participated in several meetings and discussions on evolving principles/specifications for health care reform bills being developed by congressional committees. Discussions included the following subjects: government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Office of Management & Budget (OMB); SENATE

Medicare/Medicaid MMM

Public Law 111-5, the American Recovery and Reinvestment Act of 2009 - government reimbursement for biotherapeutics S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - government reimbursement for biotherapeutics. H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - government reimbursement for biotherapeutics.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE; Executive Office of the President (EOP)

Bills named: H.Con.Res. 85 (111th), S.Con.Res. 13 (111th)

Pharmacy PHA

H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics. H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics. S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - FDA approval of follow-on biologics. H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - FDA approval of follow-on biologics.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; Executive Office of the President (EOP)

Bills named: S. 726 (111th), H.Con.Res. 85 (111th), H.R. 1548 (111th), H.R. 1427 (111th), S.Con.Res. 13 (111th)

Medical/Disease Research/Clinical Labs MED

Public Law 111-5, the American Recovery and Reinvestment Act of 2009 - funding for comparative effectiveness research. Draft legislation - the Comparative Effectiveness Research Act - authorization for comparative effectiveness research. S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - government uses of comparative effectiveness research. H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - government uses of comparative effectiveness research.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Bills named: H.Con.Res. 85 (111th), S.Con.Res. 13 (111th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
ROCHE HOLDING, LTD. Switzerland Switzerland 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.